Pharma Predictions - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharma Predictions

Pharmaceutical Technology



Ahead in active pharmaceutical ingredients: "The opportunities lie" in biologics-based drug candidates, and "the innovation is in" emerging or small- to medium-sized pharmaceutical companies.

Ahead in analytical technology: "[Supercritical fluid chromatography] is maturing for analytical and preparatory chromatography."

Ahead in outsourcing: Readers felt that outsourcing, including "mergers," "India and China," and "clinical/biological testing outsourcing," would have a major impact on industry as it allows for "cheaper" costs, "increased flexibility," and "more independent firms." Others felt outsourcing was leading to a "shutdown of Big Pharma manufacturing sites," and job loss.


Photo Credit: Photos.com
Ahead in dosage forms: "The [technique] of developing a solid dosage from a liquid version, even though it is very advanced, is still in its beginning stages."

Ahead in manufacturing: "We hope the [Critical Path Initiative] will speed up approval times." "Pharmaceutical companies need to keep their investigation of new drugs to compensate for the competition of generic drugs." "ICH [International Conference on Harmonization] is now the benchmark for determining regulatory requirements." "The formation of the EP [European Pharmacopoeia] is leveling, but has not leveled, the playing field." And, said another participant, "[The EP] will help the harmonization process... [and] facilitate global drug development markedly."

Ahead in compression technologies: "We are definitely seeing the desire for using APIs [active pharmaceutical ingredients] in combination [for bi- and tri-layered tablets.]"

Ahead in containment: "...There is more awareness of extracting, leaching, and cleaning residues contamination. There appears to be a drive to do real-time surfaces analysis."

Ahead in analytical testing: "More advanced water testing instruments are gaining acceptance in pharmaceutical laboratories."

Ahead in process development: "Green chemistry is openly challenging the best minds to look for greener alternatives to current chemical issues."

See the July 2007 issue for more coverage of the 30th Anniversary Survey.

Your opinion matters.

To contribute to this column, send your proposal to
.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here